Alto Neuroscience News and Activities

Alto Neuroscience is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Alto Neuroscience is a company listed under the stock ticker ANRO (US).

Acquisition, funding and merger involving Alto Neuroscience.

• Alto Neuroscience has just announced a $50 Million fundraising (posted on October 21 2025).

View the org chart displaying its 24 main executives

Most searched biographies at Alto Neuroscience

• Amit Etkin, Chief Executive Officer
• Christopher Cox, Director
• Husseini Manji, Director

Popular executive movements at Alto Neuroscience

• Andrew Miller has joined the company as Director  (posted on May 28 2026).

Create your alert
to follow the executive moves at Alto Neuroscience.

Alto Neuroscience has 2,431 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• AdvanCell has just announced a $315 Million fundraising (posted on July 21 2026).
• Allotera Therapeutics has just announced a $35 Million fundraising (posted on July 21 2026).
• Draig Therapeutics has just announced a $65 Million fundraising (posted on July 21 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Alto Neuroscience

• Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
• Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
• Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
• Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
• Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
• Alto Neuroscience Announces Participation in Upcoming Investor Conferences
• Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
• Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
• Alto Neuroscience Announces $120 Million Private Placement Financing
• Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
• View more press releases Close

Social media about Alto Neuroscience

• Alto Neuroscience on Wikipedia, Google News & Yahoo Finance
• Alto Neuroscience on LinkedIn, X (Twitter) & YouTube